文献速递血栓与止血

阿伐曲泊帕治疗非血液系统恶性肿瘤患者化疗所致血小板减少症:一项国际、随机、双盲、安慰剂对照的3期试验

Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2022-01-01

这项国际随机双盲安慰剂对照3期试验纳入122例接受化疗的非血液系统恶性肿瘤(卵巢癌、膀胱癌或肺癌)伴严重血小板减少症患者,按2:1随机分配至口服阿伐曲泊帕60 mg组(n=82)或安慰剂组(n=40)。主要复合终点在阿伐曲泊帕组与安慰剂组间无显著差异(意向治疗人群:57/82[70%] vs 29/40[73%],差值-3.0%[95%CI -21.6至15.6],p=0.72)。作者认为在该相对未广泛接受化疗的人群中,阿伐曲泊帕与安慰剂的血小板减少症治疗结局相似,并建议在更持续性化疗所致血小板减少症人群中评估阿伐曲泊帕。

要点

  • 阿伐曲泊帕组与安慰剂组主要复合终点应答比例无显著差异(70% vs 73%,差值-3.0%,p=0.72)。
  • 阿伐曲泊帕组严重不良事件18%(15/82),安慰剂组20%(8/40),两组均以血小板减少症最常见。
  • 作者认为在相对未广泛接受化疗人群中,阿伐曲泊帕与安慰剂治疗结局相似;需在更持续性血小板减少症人群中评估。

核心结论

  • 在相对未广泛接受化疗的非血液系统恶性肿瘤患者中,阿伐曲泊帕组与安慰剂组的化疗所致血小板减少症治疗结局相似。
  • 鉴于其安全性和提升血小板计数的能力,作者认为有必要在更持续性化疗所致血小板减少症人群中评估阿伐曲泊帕。

研究设计与样本

  • 国际、随机、双盲、安慰剂对照3期试验,在7个国家(中国、匈牙利、波兰、俄罗斯、塞尔维亚、乌克兰、美国)的71家医院或癌症治疗中心进行。
  • 纳入18岁及以上、患卵巢癌、膀胱癌或肺癌、正在接受化疗且血小板计数低于50×10^9/L的严重血小板减少症患者。
  • 按2:1随机分配至口服阿伐曲泊帕60 mg每日一次或口服安慰剂每日一次,化疗前5天及化疗后5天给药,随机化按化疗药物数量分层。
  • 2018年10月12日至2020年6月28日共入组122例,阿伐曲泊帕组82例,安慰剂组40例;中位随访31天(IQR 22-61)。
  • 主要复合终点为研究治疗至下一周期开始期间,不需血小板输注、不需因血小板减少症而降低化疗剂量≥15%或延迟化疗≥4天的应答者比例;在意向治疗和符合方案人群进行分析。

主要发现

  • 主要终点意向治疗人群:阿伐曲泊帕组57/82(70%,95%CI 58-79)vs 安慰剂组29/40(73%,95%CI 56-85),差值-3.0%(95%CI -21.6至15.6),p=0.72。
  • 主要终点符合方案人群:阿伐曲泊帕组51/60(85%,95%CI 73-93)vs 安慰剂组27/32(84%,95%CI 67-95),差值0.6%(95%CI -20.8至22.1),p=0.96。
  • 严重不良事件:阿伐曲泊帕组15/82(18%)vs 安慰剂组8/40(20%),其中血小板减少症最常见(4/82[5%] vs 4/40[10%])。
  • 常见3-4级治疗中出现的不良事件:中性粒细胞减少症22/82(27%)vs 16/40(40%),白细胞减少症19/82(23%)vs 5/40(13%),贫血16/82(20%)vs 9/40(23%),血小板减少症16/82(20%)vs 14/40(35%)。
  • 大多数不良事件被认为与研究药物无关,未报告治疗相关死亡。

关键数值与推荐

  • 主要复合终点应答者定义为:研究治疗至下一周期开始期间,不需血小板输注、不需因血小板减少症而降低化疗剂量≥15%或延迟化疗≥4天。
  • 入组要求:既往化疗线数≤2线,ECOG体能状态评分≤2,无化疗所致血小板减少症病史。
  • 阿伐曲泊帕给药方案:口服60 mg每日一次,化疗前5天及化疗后5天给药。

临床怎么用

  • 作者认为,在该相对未广泛接受化疗的非血液系统恶性肿瘤人群中,阿伐曲泊帕与安慰剂的化疗所致血小板减少症治疗结局相似。
  • 作者建议在更持续性化疗所致血小板减少症人群中评估阿伐曲泊帕。

局限性

  • 作者指出需在更持续性化疗所致血小板减少症人群中评估阿伐曲泊帕(原文:evaluation of avatrombopag in populations with more persistent chemotherapy-induced thrombocytopenia is warranted)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-induced thrombocytopenia is common and causes chemotherapy dose reductions or treatment delays, bleeding, and suboptimal oncological outcomes. We aimed to evaluate avatrombopag, a thrombopoietin receptor agonist that increases platelet counts, in patients with non-haematological cancer and platelet counts lower than 50 ×109 cells per L. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, patients aged 18 years or older at 71 hospitals or cancer treatment centres in China, Hungary, Poland, Russia, Serbia, Ukraine, and the USA and with ovarian, bladder, or lung cancer receiving chemotherapy who had severe thrombocytopenia were randomly assigned (2:1) to oral avatrombopag 60 mg or oral placebo once daily given 5 days before and after chemotherapy, with randomisation stratified by number of chemotherapy drugs used. Patients, investigators, and data collectors were masked to group allocation. Eligibility required two previous lines of chemotherapy or fewer, an ECOG performance status of 2 or less, and no previous history of chemotherapy-induced thrombocytopenia. The composite primary endpoint was the proportion of responders not requiring platelet transfusion or either a 15% or more chemotherapy dose reduction or a 4-day or more chemotherapy delay due to thrombocytopenia following study treatment until the start of the subsequent cycle. Analyses were done on the intention-to-treat and per protocol populations. Safety was analysed in all patients who received at least one dose of avatrombopag. The trial is registered with ClinicalTrials.gov, NCT03471078, and has been completed. FINDINGS: Between Oct 12, 2018, and June 28, 2020, 122 patients were enrolled and randomly assigned to receive avatrombopag (n=82) or placebo (n=40). Median follow-up was 31 days (IQR 22-61). Similar proportions of patients reached the primary endpoint in the avatrombopag and placebo groups (intention-to-treat: 57 [70%, 95% CI 58-79] of 82 vs 29 [73%, 95% CI 56-85] of 40; difference -3·0% (95% CI -21·6 to 15·6); p=0·72; per protocol: 51 [85%, 95% CI 73-93] of 60 vs 27 [84%, 95% CI 67-95] of 32; 0·6% (95% CI -20·8 to 22·1); p=0·96). 15 (18%) of 82 patients had serious adverse events in the avatrombopag group and eight (20%) of 40 in the placebo group, of which thrombocytopenia was most common (4 [5%] of 82 and 4 [10%] of 40 patients). Common grade 3-4 treatment-emergent adverse events were neutropenia (22 [27%] of 82 and 16 [40%] of 40 patients), leukopenia (19 [23%] of 82 and 5 [13%] of 40), anaemia (16 [20%] of 82 and 9 [23%] of 40), and thrombocytopenia (16 [20%] of 82 and 14 [35%] of 40). Most adverse events were considered unrelated to study drug. No treatment-related deaths were reported. INTERPRETATION: In this population of patients with non-haematological malignancies who are relatively chemotherapy naive, chemotherapy-induced thrombocytopenia treatment outcomes were similar between the avatrombopag and placebo groups. Given its safety and ability to augment platelet counts in patients with chemotherapy-induced thrombocytopenia, evaluation of avatrombopag in populations with more persistent chemotherapy-induced thrombocytopenia is warranted. FUNDING: Dova Pharmaceuticals, a Sobi company.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Kolb-Sielecki J, Safina SZ, et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022. PMID: 35240074. doi:10.1016/S2352-3026(22)00001-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。